Multi‐omic molecular profiling guide’s efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial

This prospective phase II clinical trial (Side Out 2) explored the clinical benefits of treatment selection informed by multi‐omic molecular profiling (MoMP) in refractory metastatic breast cancers (MBCs). Core needle biopsies were collected from 32 patients with MBC at trial enrollment. Patients ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Pierobon, Mariaelena, Robert, Nicholas J., Northfelt, Donald W., Jahanzeb, Mohammad, Wong, Shukmei, Hodge, Kimberly A., Baldelli, Elisa, Aldrich, Jessica, Craig, David W., Liotta, Lance A., Avramovic, Sanja, Wojtusiak, Janusz, Alemi, Farrokh, Wulfkuhle, Julia D., Bellos, Angela, Gallagher, Rosa I., Arguello, David, Conrad, Amber, Kemkes, Ariane, Loesch, David M., Vocila, Linda, Dunetz, Bryant, Carpten, John D., Petricoin, Emanuel F., Anthony, Stephen P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732340/
https://www.ncbi.nlm.nih.gov/pubmed/34437759
http://dx.doi.org/10.1002/1878-0261.13091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732340/
https://www.ncbi.nlm.nih.gov/pubmed/34437759
http://dx.doi.org/10.1002/1878-0261.13091

Ejemplares similares